Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rocco Serrao

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of the American Academy of Dermatology|January 20, 2009
Goeckerman treatment for remission of psoriasis refractory to biologic therapyRocco Serrao, Mark D P Davis
American Journal of Clinical Dermatology|November 28, 2007
Palmar erythemaRocco Serrao, Matthew Zirwas, Joseph C English
Archives of Dermatology|October 22, 2008
Localized cutaneous mucinosis after joint replacementJustin M Haught, Rocco Serrao, Joseph C English
Skinmed|September 24, 2013
Mucinous carcinoma: a translucent blue papule on an 89-year-old manThomas J Hagele, Charles Chiang, Rocco Serrao, et al.
The American Journal of Case Reports|June 21, 2022
Long-Term Efficacy of Dupilumab in Alopecia AreataMaansi Kulkarni, Craig A Rohan, Jeffrey B Travers, et al.
Journal of Drugs in Dermatology : JDD|July 11, 2012
Multiples in dermatology: markers for special considerations in diagnosis, therapy, and prognosisJulian Trevino, Josh Grosshandler, Amy Y-Y Chen, et al.
The British Journal of Dermatology|December 11, 2025
Topical Steroid Withdrawal (TSW) Syndrome: Developing Diagnostic Criteria through a Modified Delphi MethodCynhia Hsu, Lily Guo, Derrick Adams, et al.
Journal of the American Academy of Dermatology|November 29, 2025
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trialAthanasios Tsianakas, Thierry Passeron, Nina Magnolo, et al.
Pediatric Dermatology|March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.
Pediatric Dermatology|February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled TrialLawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of the American Academy of Dermatology|January 20, 2009
Goeckerman treatment for remission of psoriasis refractory to biologic therapyRocco Serrao, Mark D P Davis
American Journal of Clinical Dermatology|November 28, 2007
Palmar erythemaRocco Serrao, Matthew Zirwas, Joseph C English
Archives of Dermatology|October 22, 2008
Localized cutaneous mucinosis after joint replacementJustin M Haught, Rocco Serrao, Joseph C English
Skinmed|September 24, 2013
Mucinous carcinoma: a translucent blue papule on an 89-year-old manThomas J Hagele, Charles Chiang, Rocco Serrao, et al.
The American Journal of Case Reports|June 21, 2022
Long-Term Efficacy of Dupilumab in Alopecia AreataMaansi Kulkarni, Craig A Rohan, Jeffrey B Travers, et al.
Journal of Drugs in Dermatology : JDD|July 11, 2012
Multiples in dermatology: markers for special considerations in diagnosis, therapy, and prognosisJulian Trevino, Josh Grosshandler, Amy Y-Y Chen, et al.
The British Journal of Dermatology|December 11, 2025
Topical Steroid Withdrawal (TSW) Syndrome: Developing Diagnostic Criteria through a Modified Delphi MethodCynhia Hsu, Lily Guo, Derrick Adams, et al.
Journal of the American Academy of Dermatology|November 29, 2025
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trialAthanasios Tsianakas, Thierry Passeron, Nina Magnolo, et al.
Pediatric Dermatology|March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.
Pediatric Dermatology|February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled TrialLawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
Pageof 1